Compare Aegon Ltd. (AEG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs Novo Nordisk A/S — how do they compare? Aegon Ltd. trades at $9.41 (market cap $14.01B), while Novo Nordisk A/S trades at $46.28 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 14.8× Aegon Ltd.'s market cap, and Aegon Ltd. pays the higher dividend (4.94%). Which is the better fit depends on your goals.
| AEG | NVO | |
|---|---|---|
Market Cap | $14.01B | $207.85B |
Sector | Financials | Health |
52-Week High | $9.53 | $63.98 |
52-Week Low | $6.79 | $35.29 |
Enterprise Value | $15.16B | $222.55B |
Dividend Yield | 4.94% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.45, down 0.84% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company maintains a P/E of 13.54 and P/S of 0.57, indicating potential undervaluation, while a strategic shift to U.S. focus and a $0.25 dividend highlight corporate stability.
The outlook is cautiously optimistic, supported by deleveraging trends and revenue growth projections to $26.9B in 2025. Risks include volatile cash flows and competitive pressures, but analyst consensus leans hold with 50% rating, suggesting steady performance amid transformation efforts.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
